Featured Editorial

  1. How Can We Develop New Treatments For Patients With Early Breast Cancer? 11/10/2025

    Intensity Therapeutics has developed a new approach to treating cancer — a therapy injected directly into tumors that kills cancer and stimulates a potent anticancer immune response.

  2. M&A In GLP-1 Technology: Practical Recommendations And Best Practices 11/4/2025

    With explosive demand, expanding indications, and rapid innovation, the GLP-1 revolution is reshaping dealmaking. Here's a practical guide for companies negotiating M&A in this arena.

  3. Drug Delivery Innovation: Getting Advanced Therapies To Patients 11/3/2025

    In this article, Fran DeGrazio recounts the evolution of drug delivery technologies as she underscores the need to innovate in the delivery of advanced therapies. Considering chronic diseases, rare diseases, and difficult-to-reach therapeutic targets, Fran offers suggestions for organizing and readying for the development and delivery of platforms, systems, and devices for next generation treatments, including personalized, precision medicines.

  4. Video Spotlight: Where Science Meets Magic with MIT Institute Professor Robert S. Langer 10/29/2025

    Drug Discovery Online interviews MIT’s Bob Langer on biomedical innovation, personalized medicine, longevity, and entrepreneurship—highlighting his journey, lab impact, and personal discipline.

  5. Developing Exosome-Based RNA Therapeutics For CNS Regeneration 10/24/2025

    Inside the effort to use exosomes as natural nanocarriers that deliver RNA therapeutics safely across the blood–brain barrier to heal damaged neural tissue.

  6. CMC For Long-Acting Injectables For TB 10/3/2025

    Long-acting injectables are a potential treatment alternative for tuberculosis, but they require key development considerations from a chemistry, manufacturing, and controls perspective.

  7. Drug Delivery Product Strategy: Aligning The Organization For Execution 10/1/2025

    In this article, Fran DeGrazio offers recommendations to biopharmaceutical sponsor companies about best practices for aligning strategic product initiatives with functional area execution. She outlines 5 key considerations, illustrated with the increasingly common market strategy expansion from drug product development to drug-device combination product delivery.

  8. EU MDR: When Products Without An Intended Medical Purpose Meet Medicinal Substances 9/24/2025

    One major change introduced by the EU MDR compared to the former European directives is the inclusion of products without an intended medical purpose but with similar risk profiles to medical devices, such as dermal fillers.

  9. The Companion Diagnostic Strategy That Combination Product Leaders Need 9/17/2025

    In the U.S., the Office of Combination Products assigns primary jurisdiction for in vitro diagnostics (CDER, CBER, or CDRH). This article shares regulatory and commercial considerations.

  10. Beyond The Inhaler: Expanding COPD Care With Nebulized Combination Therapy 9/3/2025

    Seventy-five percent of COPD patients can't use inhalers properly — yet all therapies rely on handheld devices. Nebulized combinations could bridge this gap for those who need it most.